Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact email@example.com.
SOURCE Quanta Fluid Solutions Ltd
Four internationally renowned renal care specialists to assist Quanta as it prepares for the clinical introduction of its advanced haemodialysis system
ALCESTER, England, August 12, 2014 /PRNewswire/ --
Quanta Fluid Solutions Ltd ("Quanta" or the "Company"), a pioneering developer of advanced haemodialysis systems, today announces it has appointed four leading renal experts to its newly established Medical Advisory Board. Prof. John Agar, Dr. Roger Greenwood, Dr. Clara Day and Mr. Tony Goovaerts will support Quanta in the final stages of development of its SC+ system and subsequent clinical introduction. SC+ is Quanta's high performance, portable, compact haemodialysis system.
John E. Milad, Chief Executive Officer of Quanta, said "We are delighted to have secured the support and guidance of four of the most experienced and internationally revered renal care specialists. The calibre of our newly established medical advisory board demonstrates the esteem that the renal care community has in the potential of the SC+ system to create a paradigm shift in dialysis and the way patients are treated. I look forward to working with the Medical Advisory Board to further align Quanta's strategy for payors, physicians and patients as we progress towards commercialisation."
John Agar is a practising clinical nephrologist and is currently Clinical Conjoint Professor of Medicine at the Deakin University School of Medicine and Barwon Health in Geelong, Australia. He is a renowned nocturnal home haemodialysis specialist and sits on the Clinical Advisory Boards of Fresenius Medical Care and Baxter Healthcare. He is a Clinical Associate Professor of Medicine at the University of Melbourne and until recently was Senior Transplant Physician to the Transplant Service at St. Vincent's Hospital, Melbourne (1991-2013).
John has been widely published in peer-reviewed literature on the medical and economic benefits of nocturnal home haemodialysis and is a recognised leader in the expansion of this innovative therapy in Australia. In 2009, he was awarded the Order of Australia Medal for services to renal medicine.
Roger Greenwood is a Consultant Nephrologist at the Lister Hospital in Stevenage. Roger established the renal unit at Lister Hospital in 1988 and has been Clinical Director of Renal Services at the hospital for more than 20 years. Roger was previously President of the British Renal Society, Chairman of the Kidney Alliance and a member of the External Reference Group of the Renal National Service Framework. He is currently a member of the national Clinical Reference Group (dialysis) advising NHS England on the transition of Specialised Services Commissioning into new NHS structure and is also a member of the East of England Clinical Senate Assembly which provides clinical advice and strategic leadership to the local health economy. His main areas of interest in clinical research and service development include haemodiafiltration, self-care home haemodialysis, non-dialytic conservative management and end-of-life issues.
Clara Day is a Consultant Nephrologist at the Queen Elizabeth Hospital in Birmingham. After graduating from the University of Oxford in 1995, she trained as a nephrologist in the West Midlands and was awarded a PhD in renal immunology from the University of Birmingham in 2007, becoming a Consultant at Queen Elizabeth Hospital in 2008. She has clinical interests in inflammatory renal diseases, pregnancy and renal disease and haemodialysis.
Tony Goovaerts is a Certified Nephrology Nurse and holds over 40 years of experience of renal care. He is Nurse Manager of the Home Haemodialysis, Peritoneal Dialysis and Pre-treatment Counselling Programmes and of a self-care haemodialysis satellite unit at the University Hospital St Luc in Brussels, Belgium. Previously, he was a committee member of the European Dialysis and Transplant Nurses Association/European Renal Care Association (EDTNA/ERCA) and was President of the XX Annual EDTNA/ERCA Conference in Brussels, Belgium. Tony was a co-founder of the World Foundation for Renal Care, where he was Vice-President from 1996 to 2002.
Quanta is developing advanced haemodialysis systems for use in the clinic and the home. The Company's cartridge-based solution SC+ is the only portable, compact haemodialysis system with the clinical efficacy and high flow rates of traditional machines. SC+ is designed to offer ease-of-use and flexibility, facilitating self-care and supporting dialysis patients across the entire continuum of care.
Quanta is privately owned and based in Alcester, UK. The Company was founded in 2008 as a spin out from the FTSE 100 engineering company IMI plc, with funding provided by a group of leading venture capital investors specialised in healthcare: NBGI Ventures, Wellington Partners, Seroba Kernel and b-to-v Partners.
Quanta is dedicated to creating a paradigm shift in renal care and to improving the lives of dialysis patients.
For more information please visit: http://www.quantafs.com
About End Stage Renal Disease and Haemodialysis:
Lifestyle choices, modern diet and increased life expectancy are all negatively impacting renal health across the globe and End Stage Renal Disease affects millions of patients worldwide. Haemodialysis is a life-saving treatment delivered to an estimated 2 million people globally -with this figure expected to double in the next decade.
At present, haemodialysis is primarily provided by specialist clinics and centres. However this means that the patient is not in control of when they can dialyse. It is clinically proven that more regular dialysis improves outcomes and quality of life for the patient, and a number of studies have shown that 30-40% of patients would be capable of performing self-dialysis.
Issues of patient benefit, cost and clinic capacity are driving the growth of home and self-care modalities of haemodialysis, but a major factor limiting the growth of self-care and home haemodialysis is the lack of convenient, portable and easy-to-use dialysis systems. SC+ addresses these issues and puts the patient at the centre, allowing them to take greater control of their treatment.
For more information about Quanta, please contact:
John E. Milad,
Chief Executive Officer
Consilium Strategic Communications
Amber Bielecka / Mary-Jane Elliott / Matthew Neal / Lindsey Neville
©2012 PR Newswire. All Rights Reserved.